Products must note that they can increase blood pressure, but boxed warnings about adverse cardiovascular events can be removed, the FDA announced.
of testosterone replacement therapy prompted the US Food and Drug Administration to require manufacturers to conduct new studies assessing the safety of products containing the hormone.that the labels for all testosterone products must change.
For one, products must note they can increase blood pressure. Studies involving ambulatory blood pressure monitoring “confirmed an increase in blood pressure with use of all testosterone products, class-wide,” the FDA said. Some products already include this risk on their labels. Other labeling changes are more reassuring, however. Boxed warnings about the risk for adverse cardiovascular events that appear on the labels of some testosterone products can be removed. of cardiovascular events including myocardial infarction and stroke in patients who received testosterone or placebo over a 2-year period.for — men with primary or hypogonadotropic hypogonadism — remains unchanged. Labels will continue to note the safety and efficacy of testosterone has not been established in children or men with age-related hypogonadism. Thomas Blackwell, MD, an internist with The University of Texas Medical Branch in Galveston, Texas, said he expects the new labeling could lead to more men with coronary artery disease and low testosterone receiving treatment to correct the deficiency. “Some cardiologists, not all, have been reluctant to agree with testosterone replacement therapy because of that black box warning,” Blackwell told. “With that being removed, you are going to see a big roadblock taken away so that more men can benefit from testosterone therapy.” after a pair of studies in 2013 and 2014 linked the use of testosterone replacement therapy to an increased risk for stroke and myocardial infarction. to healthcare professionals and patients about the potential hazard, and labels were updated to note some but not all studies had shown testosterone therapy might increase the risk for adverse cardiovascular events. In addition, regulators required further study of testosterone’s safety, which led to TRAVERSE. Investigators in 2023from the trial, which enrolled more than 5200 men with hypogonadism at high risk for heart disease. Participants were randomly assigned to receive daily transdermal testosterone gel or placebo. Testosterone did not increase the risk for myocardial infarction, stroke, or death from cardiovascular causes in the study. Atrial fibrillation, acute kidney injury, and pulmonary embolism were more common in men who received testosterone, however.Steven Nissen, MD, chief academic officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic in Cleveland, chaired the TRAVERSE trial. He said he agrees with the FDA’s labeling changes, adding the evidence does not support a boxed warning for testosterone. Still, Nissen said TRAVERSE should not be misinterpreted to suggest testosterone is safe for everybody under all circumstances. “We showed that it could be used safely in a carefully controlled environment,” Nissen toldMen in the trial gradually increased the medication until their testosterone levels reached a normal range. “If they went too high, we back titrated or even in some cases stopped the drug,” Nissen said. “What we did not show is that if you take men who do not like the way they feel at their age and give them testosterone, that’s a good thing or that it is safe,” he said. “Testosterone is not a wonder drug for aging men, and it is important for people to have reasonable expectations,” he said. “Yes, if your testosterone is low and you have a lot of symptoms, you might want to try it. But don’t expect to feel like you did when you were 18 years old.” Other recent studies, including one by Blackwell, have supported the safety of testosterone.from more than 133,000 men with hypogonadism and found testosterone replacement therapy was associated with lower rates for mortality, atrial fibrillation, stroke, and prostate cancer. Testosterone “actually may reduce your risk for many of these problems,” Blackwell said. “It is really a sea change in the way of thinking about it.” If patients experience mild elevations in blood pressure with testosterone replacement therapy, medication could help relieve hypertension, Blackwell said. “We do not start anybody on therapy with any drug and not follow them,” Blackwell said. “If we put you on a drug, we want to make sure that it’s having the effects that we want it to have.”Martin M. Miner, MD, founder of the Men’s Health Center at The Miriam Hospital in Providence, Rhode Island, said increases in blood pressure seen with testosterone in the ambulatory pressure studies “were relatively small but they were present.” Use of oral and subcutaneous testosterone products were associated with an average increase in systolic blood pressure of about 4 mm Hg and a diastolic rise of 1-1.5 mm Hg. “Any increase in blood pressure is significant because any increase in blood pressure could potentially increase what the FDA is concerned about, which is major adverse cardiovascular events,” Miner said. “Even small increases can increase that risk.” The FDA’s announcement does not affect one aspect of prescribing testosterone Miner said torments him as a physician: Off-label use. When Miner sees patients who could benefit from treatment, almost 80% of the time the prescription is off label. Most have low testosterone levels resulting from comorbid conditions like obesity, rather than problems related to the testes, hypothalamus, or parathyroid gland, for which a prescription for testosterone is indicated, he said. “We can certainly treat patients with off-label medications, but it’s not comforting to know that everything that you are doing is off label,” Miner said.“All of these things evolve over time,” Blackwell said. “This is a step, but this isn’t necessarily where it’s going to end for testosterone.” Marius Pharmaceuticals, which markets Kyzatrex capsules, indicated further studies of testosterone could be coming.the labeling changes will “accelerate Marius Pharmaceuticals’ research into additional therapeutic uses of testosterone.” In September, Marius urged regulators to remove the boxed warning on its drug, which was approved in 2022. “With the removal of this warning, patients and providers can finally have an informed, evidence-based discussion about the true benefits and risks” of testosterone therapy, Shah said. Miner has consulted for Antares Pharma, which markets a testosterone injection. The Cleveland Clinic Center for Clinical Research received funding from pharmaceutical companies to perform clinical trials that Nissen works on, but Nissen does not accept personal compensation from the companies. AbbVie and other companies funded TRAVERSE.
Testosterone Hypertension Testosterone Therapy Low Testosterone Low T Thromboembolism Stroke Cerebrovascular Accident CVA Cerebrovascular Accident (CVA) Increased Blood Pressure Myocardial Infarction Myocardial Infarction (MI) Atrial Fibrillation AF Afib A-Fib Afib Afib Atrial Fib Atrial Fibrillation (AF) Atrial Fibrillation (A-Fib)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mexico Threatens Legal Action Against Google Over 'Gulf of America' LabelingMexico is pushing back against Google's decision to label the Gulf of Mexico as 'Gulf of America' in some regions, threatening legal action if the tech giant doesn't fully restore the original name. Mexican President Claudia Sheinbaum stated that the company's policy violates Mexican sovereignty, as the U.S. only controls a portion of the gulf. Google insists that it's following longstanding mapping policies and is willing to meet with the Mexican government. This dispute has heightened tensions between Mexico and the U.S. during a period of strained relations.
Read more »
Bella Hadid Faces Backlash for Promoting Map Labeling All of Israel as PalestineSupermodel Bella Hadid is under fire for sharing an old photo of herself posing with a map that depicts all of Israel as Palestine. The photo, taken during a 2022 visit to the Qatar National Library, sparked outrage from some, including Rep. Nancy Mace, who criticized Hadid's actions. Hadid has faced criticism before for her outspoken support of Palestinians and her refusal to lose modeling jobs due to her stance.
Read more »
The Dangerous Folly of Labeling Mexican Cartels 'Terrorist Organizations'Jon Rainwater is executive director of Peace Action. For over 30 years, he has been active in campaigns on issues of peace, nuclear disarmament, social justice and environmental sustainability. Follow him on Twitter: JonRainwater
Read more »
Ripple CLO Weighs in on SEC's Meme Coin StatementRipple's top executive speaks positively of SEC labeling meme coins as collectibles
Read more »
House votes to cancel energy efficiency labeling for appliancesPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »
Physicians React to Measles Outbreaks: ‘It’s Very Frustrating’Physicians respond with masks, telehealth, parking lot clinics, and pleas to parents to vaccinate their children.
Read more »